However, previous studies have shown that the use of single-agent therapies with CDK4/6i offer only modest improvements in most cancer types, therefore clinical trials are testing CDK4/6i combined with chemotherapy across a number of malignancies, including PC [16]. Here, CDK4 is linked to pachyonychia congenita.